All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-ZP419 | Human anti-MART1 T cell receptor (M138), pCDTCR1 | Human | M138 | Human | ELAGIGILTV | HLA-A*02:01 | Lentiviral vector | |
TCR-ZP420 | Human anti-MART1 T cell receptor (M199.15), pCDTCR1 | Human | M199.15 | Human | ELAGIGILTV | HLA-A*02:01 | Lentiviral vector | |
TCR-ZP421 | Human anti-MART1 T cell receptor (M199.34), pCDTCR1 | Human | M199.34 | Human | ELAGIGILTV | HLA-A*02:01 | Lentiviral vector | |
TCR-ZP422 | Human anti-MART1 T cell receptor (TS-M138-1), pCDTCR1 | Human | TS-M138-1 | Human | ELAGIGILTV | HLA-A*02:01 | Lentiviral vector | |
TCR-ZP423 | Human anti-MART1 T cell receptor (M180), pCDTCR1 | Human | M180 | Human | ELAGIGILTV | HLA-A*02:01 | Lentiviral vector | |
TCR-ZP424 | Human anti-MART1 T cell receptor (T1-S18.45), pCDTCR1 | Human | T1-S18.45 | Human | ELAGIGILTV | HLA-A*02:01 | Lentiviral vector | |
TCR-ZP425 | Human anti-MART1 T cell receptor (TB4), pCDTCR1 | Human | TB4 | Human | ELAGIGILTV | HLA-A*02:01 | Lentiviral vector | |
TCR-ZP426 | Human anti-MART1 T cell receptor (TB5), pCDTCR1 | Human | TB5 | Human | ELAGIGILTV | HLA-A*02:01 | Lentiviral vector | |
TCR-ZP427 | Human anti-MART1 T cell receptor (T1-S18), pCDTCR1 | Human | T1-S18 | Human | ELAGIGILTV | HLA-A*02:01 | Lentiviral vector | |
TCR-ZP428 | Human anti-MART1 T cell receptor (T1-WT), pCDTCR1 | Human | T1-WT | Human | ELAGIGILTV | HLA-A*02:01 | Lentiviral vector | |
TCR-LA-ZP050 | Anti-MART1 (FWGPNCTER) TCR-Like Antibody | Human | CLA12 | Human | FWGPNCTER | HLA-A2 |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION